We will review the diagnosis, recognition, and management of PNH, and specifically in the context of the Canadian treatment landscape. Cases will be used to highlight the variable presentations of thrombotic complications. We encourage interactivity and provide the ability to participate in Q&A, polling, and...

Dr. Michael Crump Bispecific antibodies have emerged as potent new therapy for resistant aggressive lymphomas. Integration of this new class of immunotherapy agents into the DLBCL algorithm represents new opportunities and new challenges, including timing relative to other treatments in the relapsed setting, and the...